Twist Bioscience Q2 2024 GAAP EPS $(0.79) Beats $(0.81) Estimate, Sales $75.302M Beat $70.655M Estimate
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience (NASDAQ:TWST) reported Q2 2024 earnings with a smaller loss per share of $(0.79) compared to estimates of $(0.81) and a 24.04% improvement from last year. Sales reached $75.302M, surpassing estimates of $70.655M and marking a 25.13% increase from the previous year.
May 02, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience reported a smaller than expected Q2 2024 loss and higher sales, indicating strong year-over-year growth.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can drive the stock price up in the short term. The significant improvement in losses and sales compared to the previous year further strengthens the case for a positive impact on TWST's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100